Immunomodulation - a disease-modifying avenue for treatment of Huntington's disease?

2016 ◽  
Vol 137 (5) ◽  
pp. 670-672 ◽  
Author(s):  
Maria Björkqvist
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Disease Modifying

Brain Bio-Energetic State Does Not Correlate to Muscle Mitochondrial Function in Huntington’s Disease

2020 ◽  
Vol 9 (4) ◽  
pp. 335-344
Author(s):  
Marcus P.J. van Diemen ◽  
Ellen P. Hart ◽  
Pieter W. Hameeteman ◽  
Emma M. Coppen ◽  
Jessica Y. Winder ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Mitochondrial Function ◽  
Rating Scale ◽  
Pearson Correlation ◽  
Cag Repeats ◽  
Resonance Spectroscopy ◽  
Motor Score ◽  
Energetic State ◽  
Disease Modifying

Background: Huntington’s disease (HD) is a neurodegenerative disease with cognitive, motor and psychiatric symptoms. A toxic accumulation of misfolded mutant huntingtin protein (Htt) induces mitochondrial dysfunction, leading to a bioenergetic insufficiency in neuronal and muscle cells. Improving mitochondrial function has been proposed as an opportunity to treat HD, but it is not known how mitochondrial function in different tissues relates. Objective: We explored associations between central and peripheral mitochondrial function in a group of mild to moderate staged HD patients. Methods: We used phosphorous magnetic resonance spectroscopy (31P-MRS) to measure mitochondrial function in vivo in the calf muscle (peripheral) and the bio-energetic state in the visual cortex (central). Mitochondrial function was also assessed ex vivo in circulating peripheral blood mononuclear cells (PBMCs). Clinical function was determined by the Unified Huntington’s Disease Rating Scale (UHDRS) total motor score. Pearson correlation coefficients were computed to assess the correlation between the different variables. Results: We included 23 manifest HD patients for analysis. There was no significant correlation between central bio-energetics and peripheral mitochondrial function. Central mitochondrial function at rest correlated significantly to the UHDRS total motor score (R = –0.45 and –0.48), which increased in a subgroup with the largest number of CAG repeats. Discussion: We did not observe a correlation between peripheral and central mitochondrial function. Central, but not peripheral, mitochondrial function correlated to clinical function. Muscle mitochondrial function is a promising biomarker to evaluate disease-modifying compounds that improve mitochondrial function, but Huntington researchers should use central mitochondrial function to demonstrate proof-of-pharmacology of disease-modifying compounds.

Huntington’s disease

2020 ◽  
pp. 83-92
Author(s):  
Juliana R Dutra ◽  
Tanya P Garcia ◽  
Karen Marder
Keyword(s):  
Clinical Trials ◽  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Trinucleotide Repeat ◽  
Neurodegenerative Disorder ◽  
Genetic Mutation ◽  
Current Standard ◽  
Disease Modifying ◽  
Disease Modifying Agents ◽  
A Current

Huntington’s disease (HD) is an autosomal dominant, neurodegenerative disorder caused by an unstable expansion in the cytosine adenine guanine (CAG) trinucleotide repeat in the huntingtin gene. The disease onsets gradually over many years and its symptoms include extrapyramidal movement disorder, cognitive impairment, and behavioural changes. Understanding the overall progression of HD is critical to designing clinical trials with possible disease modifying agents. Research in this area has exploded in the past two decades, as different multicentre studies have evaluated both clinical and biological measures in individuals at different stages of the disease (i.e. at-risk for the genetic mutation, pre-manifest, and manifest HD). In this chapter, we provide readers with a current understanding of HD progression. This includes an overview of the current standard for how HD is clinically evaluated, descriptive epidemiology of the disease, genetics of HD, and a review of potential disease modifiers.

scholarly journals Striatal infusion of cholesterol promotes dose‐dependent behavioral benefits and exerts disease‐modifying effects in Huntington's disease mice

2020 ◽  
Vol 12 (10) ◽  
Author(s):  
Giulia Birolini ◽  
Marta Valenza ◽  
Eleonora Di Paolo ◽  
Elena Vezzoli ◽  
Francesca Talpo ◽  
...  
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Disease Modifying ◽  
Dose Dependent

scholarly journals Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease

2014 ◽  
Vol 3 (3) ◽  
pp. 311-316 ◽  
Author(s):  
Jody Corey-Bloom ◽  
Haiqun Jia ◽  
Alaina M. Aikin ◽  
Elizabeth A. Thomas
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Glatiramer Acetate ◽  
Disease Modifying

Delivering a disease-modifying treatment for Huntington's disease

2015 ◽  
Vol 20 (1) ◽  
pp. 50-64 ◽  
Author(s):  
Bruno M.D.C. Godinho ◽  
Meenakshi Malhotra ◽  
Caitriona M. O’Driscoll ◽  
John F. Cryan
Keyword(s):  
Huntington's Disease ◽  
Huntington’S Disease ◽  
Disease Modifying ◽  
Disease Modifying Treatment
Sign in / Sign up

Export Citation Format

Share Document